Telix at ANZSNM Annual Scientific Meeting 2025
Telix Responds to Recent U.S. Government Actions- Most Favored Nation
Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available information, there is a low likelihood of material impact to Telix’s business.
Illuccix China Phase 3 Study Completes Enrolment
Telix today announces that that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient enrolment.
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant (RAI-R) thyroid cancer.
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the SÚKL for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval provides healthcare providers in the Czech Republic with broader access to PSMA-PET imaging, using a clinically validated gallium-based radiopharmaceutical.
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
Telix announces its Annual General Meeting of shareholders to be held at
Telix’s Illuccix PSMA-PET Imaging Agent Approved in France
Telix announces its Annual General Meeting of shareholders to be held at
AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®
Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas, NV.
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Telix announces its Annual General Meeting of shareholders to be held at